Simplified Report on Equity Changes (Yang Fang)

1. Declaration of Information Disclosure Obligation

1. This report is prepared by Yang Fang in accordance with the Securities Law of the People's Republic of China, the Measures for the Administration of Acquisitions of Listed Companies, and the Guidelines for the Content and Format of Information Disclosure by Companies Issuing Securities to the Public No. 15 - Report on Equity Changes, along with other relevant laws and regulations.
2. Yang Fang has obtained the necessary authorization and approval to sign this report, and its execution does not violate any provisions of the articles of association or internal rules of the information disclosure obligor, nor does it conflict with them.
3. In accordance with the Securities Law of the People's Republic of China, the Measures for the Administration of Acquisitions of Listed Companies, and the Guidelines for the Content and Format of Information Disclosure by Companies Issuing Securities to the Public No. 15 - Report on Equity Changes, this report fully discloses the changes in equity held by the information disclosure obligor in Kunming Longjin Pharmaceutical Co., Ltd.
4. As of the date of signing this report, apart from the information disclosed in this report, the information disclosure obligor has not increased or decreased her equity in Kunming Longjin Pharmaceutical Co., Ltd. through any other means.
5. The information disclosure obligor guarantees the authenticity, accuracy, and completeness of this report and related declaration documents, committing that there are no false records, misleading statements, or significant omissions, and assumes individual and joint legal responsibility for this guarantee.

2. Table of Contents

1. Definitions
2. Introduction of the Information Disclosure Obligor
   1. Basic Information of the Information Disclosure Obligor
   2. Holdings in Other Listed Companies
3. Purpose of Equity Changes
   1. Purpose of Equity Changes
   2. Future Shareholding Plans
4. Method of Equity Changes
   1. Current Holdings of the Listed Company
   2. Basic Situation of This Equity Change
   3. Impact on Control of the Listed Company
   4. Restrictions on Shares Held by the Information Disclosure Obligor
5. Trading of Listed Shares in the Past Six Months
6. Other Significant Matters
7. Documents for Inspection

3. Definitions

In this equity change report, unless otherwise specified, the following terms have the following meanings:

• Information Disclosure Obligor refers to Yang Fang.
• Longjin Pharmaceutical, Longjin Tui refers to Kunming Longjin Pharmaceutical Co., Ltd.
• Listed Company, Company refers to Kunming Longjin Pharmaceutical Co., Ltd.
• CSRC refers to the China Securities Regulatory Commission.
• SZSE, Securities Exchange refers to the Shenzhen Stock Exchange.
• This Report, This Equity Change Report, Simplified Equity Change Report refers to the "Simplified Report on Equity Changes of Kunming Longjin Pharmaceutical Co., Ltd."
• This Transaction, This Equity Change refers to the increase in shareholding disclosed by the information disclosure obligor in this report.
• Yuan, Ten Thousand Yuan refers to Renminbi Yuan, Renminbi Ten Thousand.
• Unless otherwise specified, all values in this report are retained to two decimal places. Any discrepancies between the sum of individual items and the total are due to rounding.